Indicators on BCAT-IN-4 You Should Know
The principal stop stage was the protection and tolerability of sifalimumab. Therapy-emergent adverse events (AEs) and really serious AEs (SAEs) as well as their severity, final result, and any connection to the review medication have been recorded through the investigator through the entire review. AEs have been regarded prone to be linked to exam